There was no significant relationship between MSI status and age (<i>p</i> = 0.496), FIGO stage (<i>p</i> = 0.357), initial treatment (primary debulking surgery [PDS] or neoadjuvant chemotherapy) (<i>p</i> = 0.419), residual tumor after PDS or interval debulking surgery (<i>p</i> = 0.202), and expression of CD8 (<i>p</i> = 0.126), PD-L1 (<i>p</i> = 0.432), and PD-1 (<i>p</i> = 0.653).
The α-IC cell marker SLC4A1 was seen in 60% of RO and 11% of chRCC, whereas staining for the β-IC cell marker SLC26A4was negative in all but one tumor.
Pendrin was assayed by semiquantitative Western blot in thyroid membrane fractions from 25 hyper- or hypofunctioning tumors and paired normal tissue samples.
The increased NIS expression and reduced PDS expression may make radioiodine therapy more effective in patients with thyroid cancer, especially when the tumors have no or low uptake of radioiodine.
The expression of Duox proteins was related to tumor differentiation, being more frequently found in neoplastic tissues that were able to pick up radioiodine, and in those with a detectable expression of sodium iodide symporter (NIS), pendrin and TPO.